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Background: Oxidative stress and inflammation contribute to the pathophysiology of atrial fibrillation (AF). Although carvedilol has been recently 
reported to have antioxidant and anti-inflammatory properties beyond its beta-blocking action, the effects of carvedilol on AF and its underlying 
mechanisms are yet elucidated.
Methods: Dogs underwent atrial tachypacing (ATP) at 400 bpm for 2 weeks in the absence (ATP-only, N=6) and presence of carvedilol (CAR, 50 
mg/day, N=6), starting 3 days prior to ATP onset and continued throughout. Serial electrophysiological studies were performed at baseline, 1- and 
2-week of ATP and results were each compared to non-paced controls (NP, N=6). We also evaluated the value of serum derivatives of reactive 
oxidative metabolites (DROMs) as an oxidative stress marker and CRP level at the end of the study.
Results: Mean duration of induced AF (DAF) was markedly increased (from 4±3 s at baseline to 931±389 s, p<0.05), and atrial effective refractory 
period (ERP) was significantly shortened (e.g. at basic cycle length 300 ms: from 138±5 ms at basline to 98±6 ms, p<0.01) after 2- week of ATP. 
AF vulnerability (percentage of atrial sites where AF inducible by single extra stimuli) was also significantly increased after 2-week of ATP (10±6 % 
in NP vs 54±13 % in ATP-only, p<0.05). Carvedilol strongly suppressed this ATP-induced increase in DAF (41±40 s in CAR, p<0.01 vs ATP-only) and 
AF vulnerability (17±8 % in CAR, p<0.05 vs ATP-only), and attenuated ERP shortening (117±9 ms, p<0.05 vs ATP-only). DROMs were significantly 
increased in ATP-only dogs (165±7 Carr Unit vs 115±18 Carr Unit in NP, p<0.05), and carvedilol markedly prevented this increase of DROMs 
(113±12 Carr Unit, p<0.01 vs ATP-only). No significant differences were seen in CRP levels among the group. 
Conclusions: Carvedilol prevents AF promotion and attenuates atrial tachycardia remodeling possibly via its antioxidant properties, but not anti-
inflammatory action. These findings support the notion that manipulating oxidative stress by antioxidant, such as carvedilol, may represent a novel 
therapeutic approach to AF.
